Human Connectome Project

United Imaging to Unveil Industry-Leading MRI Advancements at ISMRM 2024

Retrieved on: 
Samstag, Mai 4, 2024
Pelvis, Jupiter, FDA, Brain, ADEPT, Abdomen, Radiology, HCP, Radio, Acceleration, Radiation, AI, Human Connectome Project, Heart, Software, Neuroscience, Ultra, Research, 3D, Artificial intelligence, Signal-to-noise ratio, Intelligence, Joint, ACS, UMR, MSK, Gold, MRI, Environment, Sagitta, Health, Diagnosis, 2D, Medical imaging

SHANGHAI, May 3, 2024 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, will unveil its latest MRI technology, boasting incredible advancements across various fronts, as a Gold sponsor at this year's ISMRM meeting.

Key Points: 
  • SHANGHAI, May 3, 2024 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, will unveil its latest MRI technology, boasting incredible advancements across various fronts, as a Gold sponsor at this year's ISMRM meeting.
  • "United Imaging has always been dedicated to pushing boundaries and driving innovation," says Dr. Al Zhang, Ph.D, Chairman & Co-CEO.
  • It transcends the traditional constraints of ultra-high-field MRI, previously confined to imaging of the brain and selected MSK joints.
  • For the "Artificial Intelligence" section, United Imaging highlights the uAIFI Technology Platform, an innovative end-to-end technology platform that revolutionizes MRI through AI-integrated hardware and software.

Soterix Medical Announces Patient Recruitment for Parcel-Guided rTMS Depression Trial

Retrieved on: 
Montag, Mai 8, 2023
Columbia University, Depression, TMS, SMI, National Institutes of Health, Multimedia, HCP, MRI, Human Connectome Project, Patient, Transcranial magnetic stimulation, Principal, FDA, Pharmaceutical industry, Medical device

For the trial, SMI is actively enrolling individuals who received but did not adequately respond to repetitive Transcranial Magnetic Stimulation (rTMS) .

Key Points: 
  • For the trial, SMI is actively enrolling individuals who received but did not adequately respond to repetitive Transcranial Magnetic Stimulation (rTMS) .
  • SMI with technology licensed from Columbia University is developing a cloud-based targeting software based on parcel-guided rTMS (pg-rTMS).
  • Dr. Abhishek Datta, CEO and CTO of Soterix Medical explains, "Parcel-guided rTMS represents a major technical advance in rTMS therapy by combining three unique SMI technologies.
  • Dr. Dennis Truong, Scientist at Soterix Medical and Principal Investigator of the project says, "We are excited for this next stage in the validation of parcel-guided rTMS therapy for depression.

Soterix Medical Announces award of Fast Track NIH grant to develop a Parcel-Guided software to improve efficacy of rTMS treatment for Depression

Retrieved on: 
Donnerstag, Oktober 13, 2022
National Institute, Connectome, Depression (mood), TMS, National Institute of Mental Health, NIMH, Patient, Depression, Transcranial magnetic stimulation, Technology, Software, Columbia University, SMI, Human Connectome Project, Neuronavigation, Fast Track, HCP, Mental health, FDA, Principal, Pharmaceutical industry

The award implements a personalized parcel-guided repetitive Transcranial Magnetic Stimulation (rTMS) approach through cloud-based targeting software and validates performance in clinical trials in patients with treatment resistant depression at Columbia University.

Key Points: 
  • The award implements a personalized parcel-guided repetitive Transcranial Magnetic Stimulation (rTMS) approach through cloud-based targeting software and validates performance in clinical trials in patients with treatment resistant depression at Columbia University.
  • Soterix Medical's award is for $910,000 over two years, expandable by an additional $1.4 million for follow-on pivotal clinical trials.
  • Our ultimate goal is to develop an FDA approved targeting algorithm for standard TMS-resistant Treatment resistant Depression."
  • Soterix Medical already holds FDA clearance for Neuronavigation that is intended for the accurate positioning of treatment coil during rTMS.